treatment group

[키워드] 1:1 Administered adverse event allergy Amiodarone Anosmia Antiviral attending physician baseline blinded Blinding block childbearing age clarithromycin clinical clinical and laboratory parameters clinical care clinical trial Cobicistat coin conducted control group correlation cough COVID-19 COVID-19 disease COVID-19 patient COVID-19 pneumonia COVID-19 progression criteria Critical current cyclosporine CYP3A4 daily dose death determine determined by diagnosed diagnostic test Diltiazem dissemination dose drug early treatment Efficacy element Eligible patients emergency services enrolled epidemiologist erythromycin evaluate expected Fever follow-up visits generate hospital Hospitalization IgA IgG IgM IIa immune response immunomodulatory in vivo include inclusion criteria Indinavir Infection Informed consent inhibitor Intervention intestinal investigator investigators involved itraconazole Ivermectin ketoconazole laboratory parameter less list lung magnitude medical staff nasopharyngeal nasopharyngeal specimen Nasopharyngeal swab nasopharyngeal swab PCR nasopharyngeal swabs National negative number objective Older outcome oxygen oxygen saturation Parallel Arm participant Patient patients patients with SARS-CoV-2 PCR PCR cycle Peru Pharmacist phase Placebo placebo group placebo-controlled trial Pneumonia positive positive PCR test positive SARS-CoV-2 PCR pregnancy test pregnant women principal investigator progression proportion protocol quinidine randomization list Randomized Randomized controlled trial Randomly Rapid diagnostic test receive recruited reduce Registered Registration Result risk factor Risk factors Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 RNA SARS-CoV-2 viral load secondary Secondary objectives Seroconversion Seven severe disease severity spironolactone statistician status study population Study protocol supplementary material Symptom symptomatic Symptomatology Symptoms tacrolimus the patient the placebo group the SARS-CoV-2 threshold Treatment treatment group treatment groups treatment initiation Trial Trial registration two group two groups verapamil Viral Viral load virus Warfarin website with COVID-19 women
[DOI] 10.1186/s13063-021-05236-2 PMC 바로가기 [Article Type] Letter